What payers will ask
Is the clinical benefit the kind payers reward? — Clinical effectiveness
The evidence from the phase 3 EV-302 trial demonstrates that enfortumab vedotin with pembrolizumab significantly improves progression-free survival (PFS) and overall survival (OS) compared to platinum-based chemotherapy, with hazard ratios of 0.481 and 0.513 respectively. This indicates a major therapeutic advance with compelling evidence of substantially superior outcomes across key endpoints.
Does the economic case hold at the expected price? — Cost effectiveness
The cost-effectiveness estimates for enfortumab vedotin with pembrolizumab are within the acceptable range for NHS resources, with the committee concluding that the most plausible ICER is around £30,000 per QALY gained, which is defensible given the clinical benefits.
Is there quality-of-life evidence payers weigh? — Quality of life
The trial data indicate that enfortumab vedotin with pembrolizumab leads to improvements in quality of life, as evidenced by patient and clinical expert testimonies. The treatment is perceived to be better tolerated than traditional chemotherapy, suggesting strong quality-of-life gains.
Does the safety profile hold up for payers? — Safety and Adverse Effects
The safety profile of enfortumab vedotin with pembrolizumab is acceptable, with manageable adverse events reported. While there are potential side effects, they are generally easier to tolerate than those associated with traditional chemotherapy, indicating good tolerability.
Was the drug compared against what payers expect? — Comparator Selection
The treatment was compared against appropriate standard-of-care alternatives, specifically platinum-based chemotherapy, which is the current first-line treatment for the target population. This alignment with clinical practice supports the robustness of the evidence.
Is the population defined the way payers need it? — Patient Population and Subgroups
The trial population is broadly representative of the intended patient population, with subgroup analyses conducted based on cisplatin eligibility. However, some limitations exist regarding the generalizability of the results to all demographics.
Does the drug fit how care is delivered and paid for? — Care Pathway Integration
Enfortumab vedotin with pembrolizumab can be integrated into existing care pathways with minor adjustments, as it aligns with current treatment protocols for unresectable or metastatic urothelial cancer.
Are the wider system costs understood? — Resource Use and Cost Implications
The budget impact is manageable, and the treatment is expected to provide value for money within the NHS framework. The economic model supports the sustainability of resource use associated with this therapy.
Would the evidence survive payer scrutiny? — Evidence Quality and Robustness
The evidence base is strong, supported by a rigorous phase 3 RCT (EV-302) with low bias risk. The results are consistent and have been corroborated by real-world data, enhancing the credibility of the findings.
How exposed is the case to uncertainty? — Uncertainty, Sensitivity, and Broader Impacts
While there are some uncertainties regarding the economic model and treatment effect waning, the overall context supports the use of the treatment due to the high unmet need in this patient population.
